SCHEDULE 13G/A 0001104659-23-050861 0001802528 XXXXXXXX LIVE 4 Common Stock, par value $0.001 per share 06/30/2025 0001672619 ENLIVEN THERAPEUTICS, INC. 29337E102 6200 Lookout Road Boulder CO 80301 Rule 13d-1(c) Fairmount Funds Management LLC DE 0.00 3711444.00 0.00 3711444.00 3711444.00 N 6.3 IA The shares reported herein for the Reporting Person represent 3,711,444 shares of the Issuer's Common Stock held by Fairmount Healthcare Fund II LP ("Fund II"). The percentage calculation is based upon 58,959,717 shares of the Issuer's Common Stock outstanding as of June 16, 2025. Fairmount Healthcare Fund II L.P. DE 0.00 3711444.00 0.00 3711444.00 3711444.00 N 6.3 PN The shares reported herein for the Reporting Person represent 3,711,444 directly owned shares of the Issuer's Common Stock. The percentage calculation is based upon 58,959,717 shares of the Issuer's Common Stock outstanding as of June 16, 2025. Peter Harwin X1 0.00 3711444.00 0.00 3711444.00 3711444.00 N 6.3 HC IN The shares reported herein for the Reporting Person represent 3,711,444 shares of the Issuer's Common Stock held by Fund II. The percentage calculation is based upon 58,959,717 shares of the Issuer's Common Stock outstanding as of June 16, 2025. Tomas Kiselak 2B 0.00 3711444.00 0.00 3711444.00 3711444.00 N 6.3 HC IN The shares reported herein for the Reporting Person represent 3,711,444 shares of the Issuer's Common Stock held by Fund II. The percentage calculation is based upon 58,959,717 shares of the Issuer's Common Stock outstanding as of June 16, 2025. ENLIVEN THERAPEUTICS, INC. 6200 Lookout Road Boulder, CO, 80301 This Amendment No. 4 to Schedule 13G amends and restates the statements on Schedule 13G originally filed on April 27, 2023, Amendment No. 1 filed on February 14, 2024, Amendment No. 2 filed on November 14, 2024, and Amendment No. 3 filed on February 14, 2025. This joint statement on Schedule 13G (this "Statement") is being filed by Fairmount Funds Management LLC ("Fairmount"), Fairmount Healthcare Fund II L.P. ("Fund II"), Peter Harwin, and Tomas Kiselak. Fairmount, Fund II, Mr. Harwin, and Mr. Kiselak are collectively referred to herein as the "Reporting Persons." The Common Stock reported herein includes Common Stock beneficially owned directly by Fund II. Fairmount Healthcare Fund II GP LLC is the general partner of Fund II. The controlling persons of Fairmount are Mr. Harwin and Mr. Kiselak. Fairmount serves as investment adviser for Fund II and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"), of any securities of the Issuer held by Fund II. Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fund II's portfolio, including the shares of the Issuer's Common Stock reported herein. Because Fund II has divested voting and investment power over the reported securities and cannot revoke such delegation on less than 61 days' notice, Fund II disclaims beneficial ownership of the securities for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managing members of Fairmount, Mr. Harwin and Mr. Kiselak may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the securities reported in this Statement other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that any of Fairmount, Mr. Harwin, or Mr. Kiselak is the beneficial owner of such securities for any other purpose. c/o Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. Fairmount is a Delaware limited liability company. Fund II is a Delaware limited partnership. Mr. Harwin is a United States citizen. Mr. Kiselak is a Slovak Republic citizen. Y See the response(s) to Item 9 on the attached cover page(s). See the response(s) to Item 11 on the attached cover page(s). See the response(s) to Item 5 on the attached cover page(s). See the response(s) to Item 6 on the attached cover page(s). See the response(s) to Item 7 on the attached cover page(s). See the response(s) to Item 8 on the attached cover page(s). Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit A Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned and each other person executing this joint filing agreement (this "Agreement") agree as follows: (i) The undersigned and each other person executing this Agreement are individually eligible to use the Schedule 13G to which this Exhibit is attached and such Schedule 13G is filed on behalf of the undersigned and each other person executing this Agreement; and (ii) The undersigned and each other person executing this Agreement are responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of the undersigned or any other person executing this Agreement is responsible for the completeness or accuracy of the information statement concerning any other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument. Dated: August 14, 2025 FAIRMOUNT FUNDS MANAGEMENT LLC By: /s/ Peter Harwin /s/Tomas Kiselak Name: Peter Harwin Tomas Kiselak Title: Managing Member Managing Member FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC By: /s/ Peter Harwin /s/Tomas Kiselak Name: Peter Harwin Tomas Kiselak Title: Member Member PETER HARWIN By: /s/ Peter Harwin TOMAS KISELAK By: /s/Tomas Kiselak Fairmount Funds Management LLC /s/ Peter Harwin 08/14/2025 /s/ Tomas Kiselak 08/14/2025 Fairmount Healthcare Fund II L.P. /s/ Peter Harwin 08/14/2025 /s/ Tomas Kiselak 08/14/2025 Peter Harwin /s/ Peter Harwin 08/14/2025 Tomas Kiselak /s/ Tomas Kiselak 08/14/2025